关键词: 结核, 肺, 抗药性, 治疗结果

Abstract:

Using the method of retrospective investigation, data of 290 patients with high risk of drug-resistant tuberculosis registered in the Tuberculosis Outpatient Department of Beijing Center for Disease Prevention and Control from January 2012 to December 2021 were collected through the Tuberculosis Management Information System, a sub-system of Chinese Disease and Prevention Information System and Outpatient medical record system. The drug resistance of 9 kinds of drugs (isoniazid, rifampicin, ethambutol, streptomycin, levofloxacin, amikacin, capreomycin, protionamide, para-aminosalicylic acid) was analyzed. The drug resistance characteristics and treatment outcomes of high-risk groups were analyzed. The results showed that the sequence of single drug resistance of 9 antituberculosis drugs was isoniazid (35.93%, 60/167)>streptomycin (35.22%, 56/159)>rifampicin (24.04%, 50/208)>ethambutol (15.09%, 24/159)>levofloxacin (13.04%, 18/138)>capreomycin (7.25%, 10/138)>para-aminosalicylic acid (5.07%,7/138)>protionamide (4.35%, 6/138)>amycinkacin (3.62%, 5/138). The detection rate of multidrug-resistant tuberculosis was 26.95% (45/167). In Rifampicin-resistant patients, the screening rate of levofloxacin resistance was 90.00% (45/50) and the rate of levofloxacin resistance was 28.89% (13/45). Of the 290 patients, 50 changed to rifampicin-resistant treatment, 21 were re-diagnosed as suffering from non-tuberculous mycobacterium disease; The other 219 cases were still treated following the rifampicin sensitive treatment protocol, of which 194 cases were cured or completed their treatment, accounting for 88.58%. More efforts should be made to screen drug resistance among high-risk groups, especially for those who had failed treatment, should be fully screened.

Key words: Tuberculosis, pulmonary, Drug resistance, Treatment outcome